Cormorant Asset Management’s Cardiff Oncology CRDF Stock Holding History

Cormorant Asset Management’s Portfolio CRDF Stock Details CRDF Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-95,720	Closed	-$637K	–	92
2021 Q2	$637K	Sell	95,720 -54,280	-36%	-$460K	0.02%	99
2021 Q1	$1.39M	Hold	150,000	–	–	0.03%	111
2020 Q4	$2.7M	Sell	150,000 -25,000	-14%	-$439K	0.06%	96
2020 Q3	$2.48M	Buy	+175,000	New	+$1.16M	0.1%	85

Other funds holding CRDF

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Caxton Corporation Princeton, New Jersey $1.85M AUM 176.16% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return

OCA

Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Cormorant Asset Management's CRDF Position: Q3 2021 in Review

Cormorant Asset Management sold out of Cardiff Oncology (CRDF) in Q3 2021, closing a stake of 95,720 shares — an estimated $637K sold.

Cormorant Asset Management first reported a position in CRDF in Q3 2020 and held it in 4 quarters. The position peaked at $2.7M in Q4 2020. 94 funds tracked by Wall St. Rank hold CRDF as of Q3 2021.

Cormorant Asset Management reported no remaining Cardiff Oncology position as of Q3 2021 after selling out during the quarter.
Cormorant Asset Management sold 95,720 Cardiff Oncology shares in Q3 2021, an estimated $637K.
Cormorant Asset Management first reported a position in Cardiff Oncology in Q3 2020 and held it in 4 quarters.
Cormorant Asset Management's Cardiff Oncology position peaked at $2.7M in Q4 2020.
94 funds tracked by Wall St. Rank held Cardiff Oncology as of Q3 2021.

Based on Cormorant Asset Management's 13F filing for Q3 2021, filed 15 Nov 2021.